The value of electronic biofeedback combined with escitalopram in patients with depression after large-scale cerebral infarction
Objective To explore the value of electronic biofeedback combined with escitalopram in patients with depression after large-scale cerebral infarction.Methods 84 cases of depression after extensive cerebral infarc-tion were included in the study,from February 2022 to February 2023.They were randomly divided into an observation group and a control group,with 42 cases in each group.The control group was treated with escitalopram,while the ob-servation group received electronic biofeedback therapy on the basis of the control group.Evaluate and compare depres-sion,anxiety,and quality of life between two groups of patients.Results After treatment,compared with before treat-ment,the HAMD and HAMA scores of the two groups were lower,and the observation group was lower than the control group(P＜0.05).After treatment,compared to before treatment,the GQOLI-74 scores in all dimensions were higher in both groups,and the observation group was higher than the control group(P＜0.05).Conclusion The combination of electronic biofeedback and escitalopram can effectively improve anxiety,depression,and quality of life in patients with depression after large-scale cerebral infarction.
Electronic biofeedbackAcecitalopramLarge area cerebral infarctionDepressionQuality of life
NETL
NSTL
万方数据
